MARC Record from marc_columbia

LEADER: 02293mam a2200481 a 4500
001 1930391
005 20220609031434.0
008 961106s1996 nyu b 101 0 eng c
010 $a 96045654
020 $a1573310492 (paper : alk. paper)
020 $a1573310484 (cloth : alk. paper)
035 $a(OCoLC)ocm35927529
035 $9AMC6847CU
035 $a(NNC)1930391
035 $a1930391
040 $aDNLM/DLC$cDLC$dNLM$dNNC
050 00 $aQ11$b.N5 vol. 802$aRC523
060 10 $aW1$bAN626YL v.802 1996
060 10 $aWT 155$bA6435 1996
082 00 $a500 s$a616.8/31042$221
245 00 $aApolipoprotein E genotyping in Alzheimer's disease /$cedited by, Norman R. Relkin, Zaven Khachaturian, and Samuel Gandy III.
260 $aNew York, NY :$bNew York Academy of Sciences,$c1996.
263 $a9701
300 $aix, 225 pages ;$c24 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aAnnals of the New York Academy of Sciences,$x0077-8923 ;$vv. 802
500 $aBased on a conference sponsored by the National Institute on Aging and the Alzheimer's Association, held in Chicago in Oct. 1995.
504 $aIncludes bibliographical references and index.
650 0 $aAlzheimer's disease$xGenetic aspects$vCongresses.
650 0 $aApolipoprotein E$vCongresses.
650 12 $aAlzheimer Disease$xgenetics.$0https://id.nlm.nih.gov/mesh/D000544Q000235
650 22 $aApolipoproteins E$xgenetics.$0https://id.nlm.nih.gov/mesh/D001057Q000235
650 22 $aApolipoproteins E$xdrug effects.$0https://id.nlm.nih.gov/mesh/D001057Q000187
650 22 $aGenotype.$0https://id.nlm.nih.gov/mesh/D005838
655 2 $aCongress.$0https://id.nlm.nih.gov/mesh/D016423
700 1 $aRelkin, Norman R.$0http://id.loc.gov/authorities/names/n96803310
700 1 $aKhachaturian, Zaven S.$0http://id.loc.gov/authorities/names/n88097401
700 1 $aGandy, Samuel.$0http://id.loc.gov/authorities/names/n96803311
710 2 $aNational Institute on Aging.$0http://id.loc.gov/authorities/names/n80034377
710 2 $aAlzheimer's Association.$0http://id.loc.gov/authorities/names/no91005614
830 0 $aAnnals of the New York Academy of Sciences ;$vv. 802.$0http://id.loc.gov/authorities/names/n42032359
852 00 $boff,sci$hQ11$i.N42 v.802